Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Germline aberrations in critical DNA-repair and DNA damage-response (DDR) genes cause cancer predisposition, whereas various tumors harbor somatic mutations causing defective DDR/DNA repair. The concept of synthetic lethality can be exploited in such malignancies, as exemplified by approval of poly(ADP-ribose) polymerase inhibitors for treating BRCA1/2-mutated ovarian cancers. Herein, we detail how cellular DDR processes engage various proteins that sense DNA damage, initiate signaling pathways to promote cell-cycle checkpoint activation, trigger apoptosis, and coordinate DNA repair. We focus on novel therapeutic strategies targeting promising DDR targets and discuss challenges of patient selection and the development of rational drug combinations.
Description
Keywords
Journal Title
Conference Name
Journal ISSN
2159-8290
Volume Title
Publisher
Publisher DOI
Sponsorship
Wellcome Trust (092096/Z/10/Z)
Cancer Research Uk (None)